Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Case Report - Biomedical Research (2018) Volume 29, Issue 10

A case report of successful treatment of metastatic gastral neuroendocrine carcinoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib

Context: Neuroendocrine Tumor (NET) is arising from cells throughout the diffuse endocrine system. They comprise a broad family of tumors. Neuroendocrine Carcinoma (NEC) is a poorly differentiated and high-grade type. Advanced NEC has a poor prognosis due to a limited efficacy for chemotherapy and radiotherapy.

Case Presentation: We present here a 51-year-old Chinese woman initially diagnosed with advanced gastral neuroendocrine carcinoma. She accepted everolimus as the first line treatment, but progression after 1 month. And then she received two different cytotoxic chemotherapy regimens. Unfortunately, the treatment failed. Then, she received apatinib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens. This patient was partially responsive to apatinib with a dose of 500 mg daily. Tolerated drug-related side effects were observed.

Conclusion: Our findings indicate that some cases of neuroendocrine carcinoma may be responsive to antiangiogenic agent apatinib. Further large-scale prospective studies are needed to optimize the treatment.

Author(s): Li Nong, Yong-kui Lu

Abstract Full Text PDF

Get the App